Literature DB >> 12126656

Dopamine and the regulation of cognition and attention.

André Nieoullon1.   

Abstract

Dopamine (DA) acts as a key neurotransmitter in the brain. Numerous studies have shown its regulatory role for motor and limbic functions. However, in the early stages of Parkinson's disease (PD), alterations of executive functions also suggest a role for DA in regulating cognitive functions. Some other diseases, which can also involve DA dysfunction, such as schizophrenia or attention deficit hyperactivity disorder (ADHD) in children, as shown from the ameliorative action of dopaminergic antagonists and agonists, respectively, also show alteration of cognitive functions. Experimental studies showed that selective lesions of the dopaminergic neurons in rats or primates can actually provide cognitive deficits, especially when the mesocorticolimbic component of the dopaminergic systems is altered. Data from the experiments also showed significant alteration in attentional processes, thus raising the question of direct involvement of DA in regulating attention. Since the dopaminergic influence is mainly exerted over the frontal lobe and basal ganglia, it has been suggested that cognitive deficits express alteration in these subcortical brain structures closely linked to cortical areas, more than simple deficit in dopaminergic transmission. This point is still a matter of debate but, undoubtedly, DA acts as a powerful regulator of different aspects of cognitive brain functions. In this respect, normalizing DA transmission will contribute to improve the cognitive deficits not only related to neurologic or psychiatric diseases, but also in normal aging. Ontogenic and phylogenetic analysis of dopaminergic systems can provide evidences for a role of DA in the development of cognitive general capacities. DA can have a trophic action during maturation, which may influence the later cortical specification, particularly of pre-frontal cortical areas. Moreover, the characteristic extension of the dopaminergic cortical innervation in the rostro-caudal direction during the last stages of evolution in mammals can also be related to the appearance of progressively more developed cognitive capacities. Such an extension of cortical DA innervation could be related to increased processing of cortical information through basal ganglia, either during the course of evolution or development. DA has thus to be considered as a key neuroregulator which contributes to behavioral adaptation and to anticipatory processes necessary for preparing voluntary action consequent upon intention. All together, it can be suggested that a correlation exists between DA innervation and expression of cognitive capacities. Altering the dopaminergic transmission could, therefore, contribute to cognitive impairment. Copyright 2002 Elsevier Science Ltd.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12126656     DOI: 10.1016/s0301-0082(02)00011-4

Source DB:  PubMed          Journal:  Prog Neurobiol        ISSN: 0301-0082            Impact factor:   11.685


  263 in total

Review 1.  Cognitive effects of nicotine: genetic moderators.

Authors:  Aryeh I Herman; Mehmet Sofuoglu
Journal:  Addict Biol       Date:  2010-04-29       Impact factor: 4.280

2.  Dopaminergic reward system: a short integrative review.

Authors:  Oscar Arias-Carrión; Maria Stamelou; Eric Murillo-Rodríguez; Manuel Menéndez-González; Ernst Pöppel
Journal:  Int Arch Med       Date:  2010-10-06

3.  Use of siRNA in knocking down of dopamine receptors, a possible therapeutic option in neuropsychiatric disorders.

Authors:  Mohammad-Reza Noori-Daloii; Majid Mojarrad; Ali Rashidi-Nezhad; Majid Kheirollahi; Ali Shahbazi; Mehdi Khaksari; Asghar Korzebor; Ali Goodarzi; Maryam Ebrahimi; Ali Reza Noori-Daloii
Journal:  Mol Biol Rep       Date:  2011-06-03       Impact factor: 2.316

4.  Abnormal movements are associated with poor psychosocial functioning in adolescents at high risk for psychosis.

Authors:  Vijay A Mittal; Maria Jalbrzikowski; Melita Daley; Cristina Roman; Carrie E Bearden; Tyrone D Cannon
Journal:  Schizophr Res       Date:  2011-06-01       Impact factor: 4.939

5.  Fish oil supplementation during lactation: effects on cognition and behavior at 7 years of age.

Authors:  Carol L Cheatham; Anne Sofie Nerhammer; Marie Asserhøj; Kim F Michaelsen; Lotte Lauritzen
Journal:  Lipids       Date:  2011-04-22       Impact factor: 1.880

6.  Contrasting changes in DRD1 and DRD2 splice variant expression in schizophrenia and affective disorders, and associations with SNPs in postmortem brain.

Authors:  S S Kaalund; E N Newburn; T Ye; R Tao; C Li; A Deep-Soboslay; M M Herman; T M Hyde; D R Weinberger; B K Lipska; J E Kleinman
Journal:  Mol Psychiatry       Date:  2013-12-10       Impact factor: 15.992

7.  Widespread disruption in brain activation patterns to a working memory task during cocaine abstinence.

Authors:  D Tomasi; R Z Goldstein; F Telang; T Maloney; N Alia-Klein; E C Caparelli; N D Volkow
Journal:  Brain Res       Date:  2007-08-10       Impact factor: 3.252

8.  Genetically determined interaction between the dopamine transporter and the D2 receptor on prefronto-striatal activity and volume in humans.

Authors:  Alessandro Bertolino; Leonardo Fazio; Annabella Di Giorgio; Giuseppe Blasi; Raffaella Romano; Paolo Taurisano; Grazia Caforio; Lorenzo Sinibaldi; Gianluca Ursini; Teresa Popolizio; Emanuele Tirotta; Audrey Papp; Bruno Dallapiccola; Emiliana Borrelli; Wolfgang Sadee
Journal:  J Neurosci       Date:  2009-01-28       Impact factor: 6.167

9.  Potential contribution of dopaminergic gene variants in ADHD core traits and co-morbidity: a study on eastern Indian probands.

Authors:  Subhamita Maitra; Kanyakumarika Sarkar; Paramita Ghosh; Arijit Karmakar; Animesh Bhattacharjee; Swagata Sinha; Kanchan Mukhopadhyay
Journal:  Cell Mol Neurobiol       Date:  2014-03-02       Impact factor: 5.046

10.  Serotonin and catecholamines in the development and progression of heart valve diseases.

Authors:  Elliott Goldberg; Juan B Grau; Jacqueline H Fortier; Elisa Salvati; Robert J Levy; Giovanni Ferrari
Journal:  Cardiovasc Res       Date:  2017-07-01       Impact factor: 10.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.